Pharmaceuticals, Biotechnology and Life Sciences
Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has initiated a potentially pivotal Phase 2b clinical study of BPS-804 for the treatment of the orphan disease, osteogenesis imperfecta (OI) (brittle bone disease), the ASTEROID study.
CTI BioPharma has reported net loss of $19.8 million for the first quarter of 2017. The loss is decrease compared to the profit of $3.3 million for the same period in 2016.
Swedish Orphan Biovitrum (Sobi) has appointed Guido Oelkers as President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough.
Novo Nordisk has reported profit of €1.4 billion for the first quarter of 2017, which is increase of 10%.
Swedish Orphan Biovitrum (Sobi) will open a new office in Athens, Greece.
Sanofi and Regeneron Pharmaceuticals have resubmitted their Biologics License Application for Kevzara, which is an investigational human monoclonal antibody to be used for treatment of rheumatoid arthritis (RA) with adult patients.
AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes.
South Korea said on Thursday it has fined Swiss drugmaker Novartis 55.1 billion won ($48.80 million) for offering doctors kickbacks to recommend the company’s drugs, and also suspended insurance coverage for some of its drugs.
Pharmaceutical companies called on Thursday for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.
Bayer has reported net income of €2.083 million for Q1 2017 which is 37.9 percent higher comparing the same period last year.